Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Kish SJ, Boileau I, Callaghan RC, Tong J.

Eur J Neurosci. 2017 Jan;45(1):58-66. doi: 10.1111/ejn.13363. Epub 2016 Sep 5. Review.

PMID:
27519465
2.

N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data.

Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J, Wei X, Bazzan AJ, Zhong L, Bowen B, Intenzo CM, Iacovitti L, Newberg AB.

PLoS One. 2016 Jun 16;11(6):e0157602. doi: 10.1371/journal.pone.0157602. eCollection 2016.

3.

Dopamine neurons projecting to the posterior striatum form an anatomically distinct subclass.

Menegas W, Bergan JF, Ogawa SK, Isogai Y, Umadevi Venkataraju K, Osten P, Uchida N, Watabe-Uchida M.

Elife. 2015 Aug 31;4:e10032. doi: 10.7554/eLife.10032.

4.

Multipinhole collimator with 20 apertures for a brain SPECT application.

Lee TC, Ellin JR, Huang Q, Shrestha U, Gullberg GT, Seo Y.

Med Phys. 2014 Nov;41(11):112501. doi: 10.1118/1.4897567.

5.

Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Perlmutter JS, Norris SA.

Ann Neurol. 2014 Dec;76(6):769-83. doi: 10.1002/ana.24291. Epub 2014 Nov 7. Review.

6.

Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings.

Hou H, Wang C, Jia S, Hu S, Tian M.

Neurosci Bull. 2014 Oct;30(5):765-76. doi: 10.1007/s12264-014-1469-5. Epub 2014 Sep 28. Review.

7.

Positron emission tomography in the differential diagnosis of parkinsonism.

Rinne JO.

J Mov Disord. 2009 Oct;2(2):53-7. doi: 10.14802/jmd.09015. Epub 2009 Oct 30. Review.

8.

Clinical spectrum of dopa-responsive dystonia and related disorders.

Lee WW, Jeon BS.

Curr Neurol Neurosci Rep. 2014 Jul;14(7):461. doi: 10.1007/s11910-014-0461-9. Review.

9.

Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans.

Nye JA, Votaw JR, Bremner JD, Davis MR, Voll RJ, Camp VM, Goodman MM.

Nucl Med Biol. 2014 Mar;41(3):217-22. doi: 10.1016/j.nucmedbio.2013.12.013. Epub 2013 Dec 26.

10.

Altered resting state brain networks in Parkinson's disease.

Göttlich M, Münte TF, Heldmann M, Kasten M, Hagenah J, Krämer UM.

PLoS One. 2013 Oct 28;8(10):e77336. doi: 10.1371/journal.pone.0077336. eCollection 2013.

11.

Effect of subthalamic nucleus stimulation during exercise on the mesolimbocortical dopaminergic region in Parkinson's disease: a positron emission tomography study.

Nozaki T, Sugiyama K, Yagi S, Yoshikawa E, Kanno T, Asakawa T, Ito T, Terada T, Namba H, Ouchi Y.

J Cereb Blood Flow Metab. 2013 Mar;33(3):415-21. doi: 10.1038/jcbfm.2012.183. Epub 2012 Dec 5.

12.

Positron emission tomography neuroimaging in Parkinson's disease.

Loane C, Politis M.

Am J Transl Res. 2011 Aug 15;3(4):323-41. Epub 2011 Jul 10.

13.

Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.

Liu J, Zhu L, Plössl K, Lieberman BP, Kung HF.

Bioorg Med Chem Lett. 2011 May 15;21(10):2962-5. doi: 10.1016/j.bmcl.2011.03.051. Epub 2011 Mar 21.

14.

Multi-graphical analysis of dynamic PET.

Zhou Y, Ye W, Brasić JR, Wong DF.

Neuroimage. 2010 Feb 15;49(4):2947-57. doi: 10.1016/j.neuroimage.2009.11.028. Epub 2009 Nov 17.

15.

Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system.

Hatcher JM, Richardson JR, Guillot TS, McCormack AL, Di Monte DA, Jones DP, Pennell KD, Miller GW.

Exp Neurol. 2007 Apr;204(2):619-30. Epub 2007 Jan 5.

16.

Pyrethroid pesticide-induced alterations in dopamine transporter function.

Elwan MA, Richardson JR, Guillot TS, Caudle WM, Miller GW.

Toxicol Appl Pharmacol. 2006 Mar 15;211(3):188-97. Epub 2005 Jul 11.

17.

Positron emission tomography imaging of transplant function.

Brooks DJ.

NeuroRx. 2004 Oct;1(4):482-91. Review.

18.

Neuroimaging in Parkinson's disease.

Brooks DJ.

NeuroRx. 2004 Apr;1(2):243-54. Review.

19.

Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities.

Chang L, Ernst T, Speck O, Grob CS.

Am J Psychiatry. 2005 Feb;162(2):361-9.

20.

Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

Jenkins BG, Sanchez-Pernaute R, Brownell AL, Chen YC, Isacson O.

J Neurosci. 2004 Oct 27;24(43):9553-60.

Supplemental Content

Support Center